RPL3 and cancer: The results reported here extend the scenario of mechanisms of drugs as 5-FU and L-OHP that specifically impact ribosome biogenesis for the treatment of cancers lacking active p53 and highlight the importance of human rpL3 as critical mediator of cell response to chemotherapy.